The mantra for longevity-focused investors and entrepreneurs has long been that it makes better sense to focus on biological age, using biomarkers to track the body’s actual condition.
In tandem, a large cohort of startups have scaled up over the past few years with offerings aimed at slowing, sustaining or even shaving years off biological age. To date, they’ve collectively raised billions in areas like precision medicine and age-related metabolic disease.
The space is also poised to see one of its most high-profile IPOs with the upcoming debut of BioAge Labs, which develops therapeutics for obesity and other metabolic diseases by targeting the biology of human aging. The Richmond, California-based company is seeking to raise $142.5 million on Nasdaq alongside a $15 million private placement.
BioAge, as its name implies, is one of the more pure-play longevity-focused companies. Founded and led by accomplished aging researcher Kristen Fortney, it focuses on examining the impact of molecular changes that happen as people age and studying how these drive physical decline and disease. Its current leading therapeutic targets obesity.
2 Likes